Upload
helbert
View
170
Download
2
Tags:
Embed Size (px)
DESCRIPTION
Hyperparathyroidism exists in three different forms: primary, secondary and tertiary. Primary hyperparathyroidism (pHPT) is the most frequent pathological condition of the parathyroid glands and one of the most frequent endocrine disorders overall. The most probable location of parathyroid gland is posterior to the thyroid gland. The parathyroid glands produce parathyroid hormone (PTH), which is important for maintaining calcium, phosphate and vitamin D homeostasis, and ultimately bone health. Primary hyperparathyroidism is characterized by increased production and secretion of parathyroid hormone. This condition causes nephrocalcinosis, urolithiasis, osteoporosis, gastrointestinal disturbances, neuromuscular manifestation and neuropsychiatric disorders. Parathyroidectomy is the only curative treatment for pHPT. pHPT is typically caused by a solitary parathyroid adenoma (80%-90%), hyperplasia (10%) and less frequently parathyroid carcinoma (5%). Secondary hyperparathyroidism develops as a consequent to a chronic hypocalcemic condition that can be caused by renal failure, gastroinstinal malabsorption, dietary rickets and ingestion of drugs. Secondary hyperparathyroidism is a frequent and serious complication in haemodialysis patients. Tertiary hyperparathyroidism is a condition where parathyroid hyperplasia, secondary to chronic hypocalcemia, becomes autonomous with development of hypercalcemia. Tertiary hyperparathyroidism is used to designate hyperparathyroidism that persists or develops after renal transplantation. Localization of hyperfunctioning parathyroid tissue (adenomas or hyperplasia) in primary hyperparathyroidism is useful before surgery to help the surgeon localize the lesion, thus shortening the time of the procedure. Parathyroid glands can be imaged with multiple modalities, including scintigraphy, high-resolution ultrasonograhy, thin-section CT and MRI. Parathyroid scintigraphy may also be indicated for localization of hyperfunctioning parathyroid tissue in patients with persistent or recurrent disease. For this situation scintigraphy is superior to any other radiological modalities, including MRI, CT scan, ultrasonography combined with needle aspiration and also some invasive techniques like arteriography, selective venography and mediastinoscopy.
Citation preview
PARATHYROID SCAN PROCEDURE
TECHNOLOGISTNUCLEAR MEDICINE DEPARTMENT
SABAH WOMEN AND CHILDREN HOSPITAL
Where Are The Parathyroid Glands?
Typically there are four parathyroid glands located alongside and sometimes within the thyroid gland.
There are usually two parathyroid glands near the left lobe of the thyroid and two near the right lobe.
They are small, oval-shaped glands each approximately 6 x 4 x 2 mm and weighing approximately 30–50 mg., (about the size of a pea).
Nuclear medicine has an active role in the management
of patients with hyperparathyroidism by identifying the sites of excess parathyroid hormone production, that is, the localization of a probable adenoma in a patient with hyperparathyroidism.
Parathyroid adenomas are found in diverse localizations alongside, behind, and within the thyroid as well as in areas somewhat distant from the thyroid such as high or low in the neck or mediastinum. For this reason, there is a significant need for a method to accurately and non invasively identify the location of excess parathyroid hormone production.
It is important to include the entire chest in the imaging field in all parathyroid imaging protocols for evaluation of potential ectopic sites.
Parathyroid Study..
Localization of hyperfunctioning parathyroid tissue
(adenoma/ hyperplasia) in primary hyperparathyroidism is useful before surgery to help the surgeon localize the lesion, thus shortening the time of the procedure.
Localization of hyperfunctioning parathyroid tissue in patients with persistent or recurrent disease
Indication
Pregnant women
Contraindication
Discontinuation of breast feeding for nursing mothers
for 24 hours after imaging.
Precaution
Patient might be advised by Medical Officer to discontinue usage
of iodide-containing medications that can cause iodine saturation. Radiological studies with iodine-containing contrast media should
be avoided 4 weeks prior to the parathyroid scintigraphy. Treatment with Carbimazole or Propylthiouracil should be with
held 3 days prior to the scan. Thyroid replacement hormone should be discontinued for 2 weeks
prior to scan. Whereas for secondary hyperthyroidism, active Vitamin D should
be withheld for at least 1 week, native Vitamin D for 4 weeks and calcimimetics for 2 weeks prior to the scan (need to be discussed with Nuclear Medicine Specialist/Nephrologist)
Patient Preparation
99mTechnetium-sestamibi adult: 18-22 mCi 99mTechnetium-tetrofosmin adult: 18-22 mCi 99mTechnetium-pertechnetate adult: 2-10 mCi Child: As per body weight (Refer to Gilday’s Chart) Technique of administration: Intravenous Injection
Radiopharmaceutical
Protocol
Washout
Dual phase parathyroid scintigraphy exploits the different washout timing that some radiotracers show in thyroid and parathyroid tissues: to find parathyroid hyperfunctioning tissue, washout timing of radiotracer from the parathyroid must be slower than from thyroid tissue.
Subtraction99mTc-sestamibi is myocardial perfusion tracer and is taken up not only by the hyperfunctioning parathyroid glands but also by thyroid tissue. Hence, the necessity of comparison with a second tracer, which is taken up by the thyroid gland only, such as 99mTechnetium-pertechnetate. The distributions of the 2 tracers can be visually compared and, afterwards, the thyroid scan can be digitally subtracted from the parathyroid scan to remove the thyroid activity and enhance the visualization of parathyroid tissue.
PHILIPS Dual-head Gamma Camera Low Energy High Resolution (LEHR) collimator High Energy Low Resolution (Pinhole) collimator
Instrument
Make sure the Gamma Kamera room is ready. Call Patient in the post-injection room. Explain patient about the procedure. Position the patient on the table in the supine position
with a pillow positioned under the shoulders which allow the head to drop back and extends the neck. Secure the head so that it does not move from side to side.
Make sure the patient is comfortable and cover the patient with blanket before starting the procedure to ensure patient is warm.
Tell the patient not to move while performing the scan.
Procedure
Static ANT/POST 20 mins after injection of
Tetrofosmin SPECT Pinhole Static Tetrofosmin 60 mins after inject Pinhole SPECT Static Tetrofosmin delayed 2 hours after inject SPECT Pinhole [Delayed 3 hours after inject if necessary] Static Pinhole SPECT
Washout Procedure
If needed
If needed
If needed
If needed
Static ANT/POST 20 mins after injection of Tc99m SPECT Pinhole Pinhole Tetrofosmin 60 mins after inject Static SPECT Static Tetrofosmin delayed 2 hours after inject SPECT Pinhole [Delayed 3 hours after inject if necessary] Pinhole Static SPECT
Subtraction Procedure
If needed
If needed
If needed
If needed
After the completion of the scan, inform the Medical Officer in
charge to review the scan images. Be ready to repeat scan or perform additional scan if ordered
by the Medical Officer in charge. Assist the patient to get up and ask the patient to have rest
while waiting in the post-injection room. Remind patient to take plenty of water and to keep at least 1-2
meter away from children and pregnant ladies for at least 6 hours from the time of the radiopharmaceutical injection.
Inform and pass the “Penilaian Selepas Skan Radionuklid” form to the Nurse in charge at the counter or injection room regarding the patient release.
Proceed to image processing by referring to the Standard Operating Procedure of Parathyroid Scan Processing.
Cont..
International Atomic Energy Agency: Nuclear Medicine
Resources Manual, 2006 SNM Practice Guideline for Parathyroid Scintigraphy 4.0 2009 EANM Parathyroid Guidelines Distance Assisted Training Programme for Nuclear
Medicine Technologists: Parathyroid Imaging, Version 3.1
Nuclear Medicine Technology and Techniques by Donald R. Bernier, Paul E. Chstistian, James K. Langan
Preferences
Thank You